Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience

Table 3 Chemotherapy and response

AL-OHT	Rx relative to OHT	First amyloid directed therapy (Rx)	Response to1st Rx	Lines of Rx
8	Only Rx post-OHT	AHSCT1	CR	1
22	Rx pre- and post-OHT	Mel-Dex	CR	≥ 2
23	Rx pre- and post-OHT	Bortezomib-Dex3	VGPR	≥ 2
1	Only Rx post-OHT	Mel-Pred	CR	≥ 2
17	Only Rx post-OHT	AHSCT1	CR	≥ 2
9	Only Rx post-OHT	AHSCT1	CR	≥ 2
2	Only Rx pre-OHT	Mel-Pred	IFE positive	1
12	Only Rx post-OHT	AHSCT2	PR	≥ 2
3	Only Rx post-OHT	AHSCT1	CR	1
14	Only Rx post-OHT	AHSCT2	IFE positive	1
16	Only Rx post-OHT	AHSCT1	VGPR	≥ 2
7	Rx pre- and post-OHT	VBMCP	IFE positive	≥ 2
18	Only Rx post-OHT	AHSCT1	VGPR	1
5	Only Rx post-OHT	Mel-Pred	NA	1
10	No treatment	None	NA	0
19	Only Rx post-OHT	AHSCT2	PR	1
4	Rx pre- and post-OHT	Mel-Pred	IFE positive	≥ 2
21	Only Rx post-OHT	AHSCT2	No response	≥ 2
13	Only Rx post-OHT	AHSCT1	IFE positive	1
11	Only Rx post-OHT	AHSCT2	IFE positive	1
15	No treatment	None	NA	0
20	Only Rx post-OHT	Dex	CR	1
6	No treatment	None	NA	0

¹Melphalan conditioning 200 mg/m²;

²Melphalan conditioning 140 mg/m² in all but OHT #12 who got 150 mg/m²;

³Patient had AHSCT as second line and received Melphalan conditioning 200 mg/m². Amyloid directed therapy: AHSCT: Autologous hematopoietic stem cell transplant; Mel: Oral melphalan; Pred: Prednisone; Bortez: Bortezomib; Dex: Dexamethasone; VBMCP: Vincristine, BCNU, melphalan, cytoxan, prednisone; NA: Not available; CR: Complete hematologic response; PR: Partial response; VGPR: Very good partial response; IFE: Immunofixation.